

## PE Human CD19 Protein (C-Fc)

|                           |                 |
|---------------------------|-----------------|
| <b>Catalog Number:</b>    | 807401, 807402  |
| <b>Size:</b>              | 25 ug, 100 ug   |
| <b>Target Name:</b>       | CD19, B4, CVID3 |
| <b>Regulatory Status:</b> | RUO             |

### PRODUCT DETAILS

---

|                               |   |
|-------------------------------|---|
| <b>Application:</b>           | Flow Cytometry  |
| <b>Format:</b>                | Liquid, PE  |
| <b>Expression Host:</b>       | CHO   |
| <b>Species:</b>               | Human   |
| <b>Sources:</b>               | Recombinant Human CD19 Protein (Glu21-Lys291) with C-terminus Fc-tag is expressed in CHO cell and conjugated to PE.   |
| <b>Accession Number:</b>      | P15391  |
| <b>Molecular Weight:</b>      | The protein has a predicted molecular weight of 56.2 kDa. Under DTT-reducing conditions, it migrates at approximately 70-80 kDa on SDS-PAGE prior to conjugation. |
| <b>Affinity Tag:</b>          | C-Fc  |
| <b>Formulation:</b>           | 1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein  |
| <b>Endotoxin level:</b>       | Not tested  |
| <b>Protein Concentration:</b> | 25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration.   |
| <b>Storage and Handling:</b>  | Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2-8°C for up to six months.   |

### BACKGROUND INFORMATION

---

Cluster of Differentiation 19 (CD19) is a 95 kDa type I transmembrane glycoprotein and a member of the immunoglobulin superfamily, expressed on B cells from the early pro-B stage through to activated B blasts, but absent on plasma cells. It is also present on follicular dendritic cells. CD19 functions as a crucial co-receptor in B cell signaling by forming a complex with CD21 (CR2) and CD81 (TAPA-1), which enhances the sensitivity of B cells to antigens by lowering the activation threshold. Upon antigen binding, CD19 is phosphorylated, recruits Src-family kinases and PI3K, and internalizes with surface immunoglobulin (sIg), promoting downstream signal transduction necessary for B cell development, activation, and differentiation. Mutations in CD19 are linked to immunodeficiency syndromes with impaired antibody production, and CD19 is a key target in immunotherapy, particularly CAR-T cell treatment of B-cell malignancies.

### PRODUCT DATA

---

**A: CD19 CAR-transfected**  
Stained with PE-CD19-Fc

**B: Mock-transfected**  
Stained with PE-CD19-Fc

CHO cells transfected with either CD19 CAR or Mock plasmid were stained with PE conjugated CD19 (C-Fc) protein at 1ug\_test

This product is supplied subject to the terms and conditions at [www.innocyto.com/web/terms.php](http://www.innocyto.com/web/terms.php) and may only be used as provided in the stated terms. Products are for Research Use Only.